Testing a new immune therapy alone or combined with another drug for skin and blood T-cell cancers

Plain-English translation of NCT03011814 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a medication called , an immune system booster, to treat T-cell lymphomas that have not responded to previous treatments. You may receive by itself, or combined with another medication called . The study wants to find out whether these treatments can shrink the cancer and improve quality of life, especially by reducing severe itching.

Many people with T-cell lymphomas (cancers affecting immune cells) don't respond well to standard treatments, or their cancer comes back. This trial is testing whether activating the immune system with this medication can help fight these hard-to-treat cancers.

Do you qualify?

You likely qualify if…

you have been diagnosed with a T-cell lymphoma (such as mycosis fungoides, Sézary syndrome, or peripheral T-cell lymphoma) that has either not responded to treatment or has come back
you have already tried at least 2 previous systemic (whole-body) treatments for your cancer
you have recovered from side effects of your previous cancer treatments
your overall health is stable enough for treatment, with an ECOG performance status of 0–2
you have measurable disease that can be tracked by imaging, skin exams, or blood tests
you are willing to join the Revlimid REMS program (a safety monitoring system, if assigned to the combination arm)

You likely don't qualify if…

you are pregnant or breastfeeding, or unwilling to use effective birth control during the trial
you have severe liver or kidney problems
your blood cell counts are too low (unless caused by the cancer itself)
you have had a severe allergic reaction to either of the study medications

What participation looks like

You will receive infusions of the medication into your vein once every 28 days. If you are in the combination arm, you will also take a pill by mouth daily for 21 days of each cycle. The trial lasts up to 13 treatment cycles (about 1 year) and includes regular blood tests, skin exams, and biopsies to check how well the treatment is working and whether you are having side effects.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Testing a new immune therapy alone or combined with another drug for skin and blood T-cell cancers

What is this trial?

Do you qualify?

What participation looks like

Trial locations